This publication is protected and can be accessed only from certain IPs.
This publication is protected and can be accessed only from certain IPs.

Title: Development of a new recombinant fusion protein with pro-apoptotic and anti-angiogenic properties for targeted anti-cancer therapy


For almost three decades tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been under intense scientific evaluation because of its remarkable ability to induce apoptosis in cancer cells while omitting normal cells. However, its effectiveness was insufficient to become a single therapy agent. Targeting tumor angiogenesis may be a valuable addition to the TRAIL/DR-based anti-tumor strategy. Vascular endothelial growth factor (VEGF) is essential for vascular development and neovascularization both in physiological and pathological processes. Blockade of VEGF pathway has been shown to inhibit pathological angiogenesis and tumor growth. A proposed new fusion protein consists of a recombinant TRAIL variant that is linked to a duplicated sequence of effector peptides linked by flexible linkers. The effector peptide is derived from the VEGF ligand and is able to bind to VEGF receptors but lack angiogenic effect. The VCTR4.0 fusion variant shows specific in vitro cytotoxic activity against various tumor cell lines with an IC50 level of less than 1 nM. Additionally, its a very strong inducer of apoptosis in the TRAIL-resistant line, and its direct anti-angiogenic activity was confirmed in the HUVEC nodular test. The strong anti-tumor activity of the new fusion molecule was also confirmed in the MES-SA / Dx5 drug-resistant human uterine sarcoma xenograft model. A simi ; lar effect was observed in the Colo205 human colorectal adenocarcinoma, the MIA PaCa-2 human pancreatic carcinoma,and the HepG2 human liver cancer model. All these results show that a very promising molecule with a high potential for anti-cancer activity has been developed.

Place of publishing:


Level of degree:

2 - studia doktoranckie

Degree discipline:


Degree grantor:

Rada Dyscypliny Nauki farmaceutyczne


Pękala, Elżbieta

Date issued:




Call number:




Access rights:

tylko w bibliotece

Object collections:

Last modified:

Apr 8, 2024

In our library since:

Mar 31, 2022

Number of object content hits:


Number of object content views in PDF format


All available object's versions:


Show description in RDF format:


Show description in OAI-PMH format:


Edition name Date
ZB-134097 Apr 8, 2024


Citation style:

This page uses 'cookies'. More information